1. GABRP is a Promising Prognostic Biomarker and Associated with Immune Cell Infiltration in Lung Squamous Cell Carcinoma
   Jiding Fu et al, 2023, Pharmacogenomics and Personalized Medicine CrossRef
2. Ebracteolatain A Inhibits Lung Cancer Growth via p21 and p27 Mediated Cell-Cycle Arrest
   Weili Zhao et al, 2023, Natural Product Communications CrossRef
3. Identification of an antigen-presenting cells/T/NK cells-related gene signature to predict prognosis and CTSL to predict immunotherapeutic response for lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing
   Liling Huang et al, 2023, Cancer Immunology, Immunotherapy CrossRef
4. Cell-Based Vaccines: Frontiers in Medical Technology for Cancer Treatment
   Babak Arjmand et al, 2024, Regenerative Engineering and Translational Medicine CrossRef
5. BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3
   Francesca Reggiani et al, 2024, Nature Communications CrossRef
6. Platinum‐Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment
   Tao Yang et al, 2023, Angewandte Chemie CrossRef
7. Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer
   Miriam Franklin et al, 2022, Frontiers in Immunology CrossRef
8. Screening and identifying a novel M-MDSCs-related gene signature for predicting prognostic risk and immunotherapeutic responses in patients with lung adenocarcinoma
   Geng-Chong Wang et al, 2023, Frontiers in Genetics CrossRef
9. Platinum‐Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive Microenvironment
   Tao Yang et al, 2023, Angewandte Chemie International Edition CrossRef
10. A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer
    Pengyu Yao et al, 2024, Frontiers in Immunology CrossRef
11. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study
    Myeong Geun Choi et al, 2024, Journal for ImmunoTherapy of Cancer CrossRef
12. Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer
    Éilis Russell et al, 2022, Cells CrossRef
13. Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial
    Hyung Jun Park et al, 2022, Thoracic Cancer CrossRef
14. KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?
    Giuseppe Pelosi, 2021, Journal of Thoracic Oncology CrossRef
15. CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
    Ler Yie Chan et al, 2022, Biomedicines CrossRef